6,602 Shares in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. acquired a new position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,602 shares of the company’s stock, valued at approximately $40,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP bought a new stake in Acrivon Therapeutics during the 2nd quarter worth $58,000. Barclays PLC grew its position in shares of Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after buying an additional 11,273 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after buying an additional 28,748 shares during the last quarter. State Street Corp grew its position in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after buying an additional 47,233 shares during the last quarter. Finally, Exome Asset Management LLC bought a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at about $817,000. Institutional investors own 71.62% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ACRV. Cantor Fitzgerald began coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. KeyCorp initiated coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an “overweight” rating on the stock. Finally, BMO Capital Markets decreased their target price on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics presently has a consensus rating of “Buy” and an average target price of $23.67.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $5.91 on Wednesday. The business has a 50 day simple moving average of $6.28 and a 200 day simple moving average of $7.31. The stock has a market capitalization of $184.04 million, a P/E ratio of -2.19 and a beta of 0.77. Acrivon Therapeutics, Inc. has a one year low of $3.19 and a one year high of $11.90.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.